| 2022 | | Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined with Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma | 노진, 박준성, 정성현, 최윤석 |
| 2022 | | Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 | 이현우 |
| 2022 | | Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 | 강석윤 |
| 2022 | | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis | 최윤석 |
| 2022 | | Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors | 권민석 |
| 2022 | | Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study | 강석윤, 김태환, 안미선, 이현우, 최용원, 최진혁 |
| 2022 | | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) | 안미선 |
| 2022 | | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | 정성현, 최윤석 |
| 2022 | | Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations | 안미선 |
| 2022 | | Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01) | 최진혁 |
| 2022 | | Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer | 강석윤 |
| 2022 | | Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data | 강석윤, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2022 | | Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma | 고영화, 이현우, 한재호, 함석진 |
| 2021 | | A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer | 최진혁 |
| 2021 | | Characterizing the anticancer treatment trajectory and pattern in patients receiving chemotherapy for cancer using harmonized observational databases: Retrospective study | 강석윤, 박래웅 |
| 2021 | | Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma | 최윤석 |
| 2021 | | Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] | 강석윤 |
| 2021 | | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | 최진혁 |
| 2021 | | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study) | 강석윤 |
| 2021 | | Incident type 2 diabetes risk of selective estrogen receptor modulators in female patients with breast cancer | 최용원 |
